Noteworthy Friday Option Activity: CTLP, SOUN, TEM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Source: NASDAQ.COM
SoundHound AI Inc Options Trading: SoundHound AI Inc (SOUN) experienced significant options trading with 621,536 contracts, notably the $14 strike call option expiring August 08, 2025, which saw 36,946 contracts traded.
Tempus AI Inc Options Trading: Tempus AI Inc (TEM) also had high options trading volume of 136,045 contracts, particularly for the $62 strike call option expiring August 08, 2025, with 17,503 contracts traded.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 86.00 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 63.510
Low
76.00
Averages
86.00
High
105.00
Current: 63.510
Low
76.00
Averages
86.00
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
Continue Reading
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
Continue Reading